

Candidacy for Antileukemic Therapy

In determining candidacy for antileukemic therapy, consider:

Patient goals

Patient preferences

Physician recommendation

Balance of benefits & risks of therapy

Red Blood Cell Transfusion

For the older adult with AML who is no longer receiving antileukemic therapy, including those receiving end-of-life care or hospice care:

✓

The ASH guideline panel **suggests having red blood cell transfusions be available**
(vs. not having transfusions be available)

Source: 2020 ASH CPG on AML in Older Adults. The evidence for this recommendation was not rereviewed in 2025.

Remark: There may be rare instances where platelet transfusions may be of benefit in the event of bleeding, but there are even less data to support this practice and it is anticipated that platelet transfusions will have little or no role in end-of-life or hospice care.

✓

Recommends...

✗

Recommends against...

✓

Suggests...

✗


Suggests against...

Strong Recommendations		Conditional Recommendations	
Recommends...	Recommends against...	Suggests...	Suggests against...
✓	✗	✓	✗
Most individuals should follow the recommended course of action. Formal decision aids are not likely to be needed to help individual patients make decisions consistent with their values and preferences.		Different choices will be appropriate for individual patients; clinicians must help each patient arrive at a management decision consistent with the patient's values and preferences. Decision aids may be useful in helping individuals to make decisions consistent with their individual risks, values, and preferences.	

Access additional tools and resources at hematology.org/amlguidelines:


- Visual Summaries
- Teaching slides
- Infographics
- Snapshots
- Patient resources
- Podcasts
- Additional pocket guides

Reference: Sekeres M.A., Mattison R., Artz A., Baer, M.R., Chua C.C., Demichelis-Gomez R., Egan P.C., Fletcher L., Foucar C., Garcia J.S., Gilberto L., Gómez De León A., Lancet J., Loh K.P., Malcovati L., Marini B., Platzbecker U., Sorror, M.L., Tinsley-Vance S., Treitz J., Oliveros M.J., Ibrahim S., Roldan Y., Guyatt G., Brignardello-Petersen R. American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. *Blood Advances*. DOI: <https://doi.org/10.1182/bloodadvances.2025017934>

ASH CLINICAL PRACTICE GUIDELINES
ACUTE MYELOID LEUKEMIA

Acute Myeloid Leukemia


A POCKET GUIDE FOR THE CLINICIAN
2025




The recommendations in this guide are based on the American Society of Hematology 2025 Guidelines for Treating Newly Diagnosed Acute Myeloid Leukemia in Older Adults

POCKET GUIDE

Initial Antileukemic Therapy




Actionable/Targetable Mutations



Response & Remission

ASH guideline panel recommendations for the older adult with newly diagnosed AML who:



Allo-HCT: Allogeneic Hematopoietic Stem Cell Transplant; **AML:** Acute Myeloid Leukemia; **HMA:** Hypomethylating agent; **LDAC:** Low-dose Cytarabine

*Source: 2020 ASH CPG on AML in Older Adults. The evidence for this recommendation was not rereviewed in 2025.

- ✓ Recommends... ✗ Recommends against...
✓ Suggests... ✗ Suggests against...